Gedea Biotech develops pHyph to treat and prevent recurrence of bacterial vaginosis. Bacterial vaginosis (BV) is a very common condition with a prevalence of 10-30% for women of childbearing age. The symptoms can be very disturbing and include an often profuse thin, white, “fishy” smelling vaginal discharge. Standard treatment consists of antimicrobials, but recurrence rate is 15–30 % within 3 months. pHyph will treat the infection and prevent recurrence without the use of antmicrobials. Antimicrobial resistance is one of the World Health Organisation’s top ten threats to global health
and research into novel non-antimicrobial based treatments is timely.
Company Details
- Employees
- 15
- Founded
- -
- Address
- Medicon Village, Scheeletorget 2,sweden
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- gedeabiotech.com
- HQ
- Lund, Skane
Gedea Biotech Ab Questions
Gedea Biotech Ab's website is gedeabiotech.com
Gedea Biotech Ab's LinkedIn profile is https://se.linkedin.com/company/gedeabiotech
Gedea Biotech Ab has
15 employees.
View email and phone details for 15
employees at Gedea Biotech Ab.
Gedea Biotech Ab's industry is
Biotechnology Research
Gedea Biotech Ab's top competitors are
Modus Therapeutics Holding Ab,
Hamlet Biopharma,
Anocca,
Diamyd Medical,
Bioinvent International Ab,
Biolamina,
Aligned Bio,
Bioarctic,
Lu Ventures,
Xinnate.
Gedea Biotech Ab's categories are Biotechnology Research
Gedea Biotech Ab's founding year is 2015
